Research Reference
Cortexin
Polypeptide complex studied for neuroprotection and cognition
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Cortexin is a polypeptide complex studied in some countries for neuroprotection and cognitive support. It is not FDA approved.
Dosing Reference
Reconstitution
Add 1 mL bacteriostatic water to the 5 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 5 mg | 100 units | 1 mL | IM, dailyStudied neuroprotection protocol (10-day course) |
| 10 mg | 200 units | 2 mL | IM, dailyHigher studied dose |
| 5 mg | 100 units | 1 mL | IM, daily (pediatric)Studied pediatric cognitive protocols |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Cortexin is supplied as a lyophilized polypeptide complex in 5 mg or 10 mg vials, primarily in the Russian Federation and CIS markets where it is registered. It is not FDA-approved in the United States.
The lyophilized powder is reconstituted with 1–2 mL of saline or bacteriostatic water per the manufacturer's directions. For a 5 mg vial reconstituted with 1 mL, the concentration is 5 mg/mL; a 5 mg dose draws to 100 units (1 mL) on a U-100 insulin syringe. For a 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 5 mg dose draws to 100 units (1 mL). Gently swirl — do not shake — to mix. Use promptly after reconstitution per the manufacturer's directions.
Cycling Protocol
Studied protocols describe cortexin administered intramuscularly once daily for a 10-day course, sometimes repeated after a 1–6 month interval depending on indication. Pediatric cognitive protocols describe similar 10-day courses.
No long-term continuous cycling is established. The 10-day course structure is the most commonly described pattern in the published literature from regions where the compound is registered.
Routes of Administration
Intramuscular injection (established route): Administered as a daily intramuscular injection, typically into the gluteal or deltoid muscle. This is the route used in the published studies.
No subcutaneous, oral, intranasal, or intravenous human route is established. Cortexin is not orally bioavailable as a peptide complex.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Cognitive Stack | Cortexin + Cerebrolysin | Combined neuroprotection / nootropic (studied in CIS literature) | | Neuro Recovery | Cortexin + Pinealon | Cortex + pineal peptide bioregulators | | Vascular Cognitive | Cortexin + Vinpocetine / Ginkgo | Combined neurovascular support |
Stacking combinations are described in the CIS-region literature where these compounds are registered. They are not FDA-approved and are not validated in US clinical trials.
Side Effects & Safety
- Injection-site reactions — redness or mild pain at the injection site, the most commonly reported effect
- Allergic/hypersensitivity reactions — rare
- Generally described as well-tolerated in the published CIS-region literature at studied doses
- No large US safety database — the compound is not FDA-approved and Western safety data is limited
Cortexin is not FDA-approved in the United States. It is registered in some other countries. Compounded research-peptide forms are not FDA-approved and are sold for research purposes only.
Research Basis
Cortexin is a complex of low-molecular-weight peptide fractions derived from the cerebral cortex of animals, developed and registered in the Russian Federation and CIS countries.
Mechanism: Described as exerting neuroprotective, nootropic, and antioxidant effects, with tissue-specific action on brain tissue in the bioregulator peptide tradition.
Clinical evidence: Published studies, primarily from the CIS region, describe use in cognitive impairment, stroke recovery, traumatic brain injury, and pediatric neurodevelopmental contexts, often as 10-day intramuscular courses.
Not FDA-approved: Cortexin is not approved by the FDA in the United States, and the body of published research is largely outside US regulatory and trial frameworks. Compounded research-peptide forms are sold for research purposes only.